Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2initiatives for SYI-2074 (formerly ALT-2074) in cardiovascular diseases,alagebrium in heart failure and diabetic nephropathy and progress on thecompany's Haptoglobin diagnostic test. He will also provide an update ofrecent milestones and executive appointments.
The presentation will be simultaneously webcast and can be viewed live onthe investor relations section of the Company's website at www.synvista.com .Participants are encouraged to log on to the webcast approximately five to tenminutes prior to the start of the presentation. It will be archived thereafter the event.
Note to Attendees: Synvista will be available for one-on-one meetings.Please arrange through Rodman & Renshaw or by calling Kim Sutton Golodetz orJules Abraham at Lippert/Heilshorn & Associates at 212-838-3777.
The conference will feature presentations from more than 150 public andprivately held emerging growth healthcare companies presenting data on anarray of therapeutic topics including oncology, cardiovascular disease,central nervous system disorders, infectious diseases and medical devicetechnology. Details regarding the conference can be obtained atwww.rodmanandrenshaw.com .
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing drugs totreat and prevent cardiovascular disease and nephropathy in people withdiabetes. The Company believes it has identified several product candidatesthat represent novel approaches to some of the largest pharmaceutical markets.The Company's portfolio includes orally bioavailable, organoselenium mimics ofglutathione peroxidase. These compounds metabolize lipid peroxides and havethe potential to limit myocardial damage subsequent to a myocardialinfarction. The Company is developing a clinical diagnostic test, based oncardiovascular risk assessment, using Haptoglobin characterization, toidentify patients at high risk for cardiovascular complications of diabetes.
Synvista Therapeutics is also developing alagebrium, a proposed breaker ofAGEs for the treatment of diastolic heart failure. This disease represents arapidly growing market of unmet medical need, particularly common amongdiabetic patients. Alagebrium has demonstrated relevant clinical activity intwo Phase 2 clinical trials in heart failure, as well as in animal models ofheart failure and nephropathy, among others. Alagebrium has been tested inapproximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials,allowing Synvista Therapeutics to assemble a sizeable human safety database.For more information, please visit the Company's website at www.synvista.com .
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements that involve risksand uncertainties including, but not limited to, the risks associated with theevents described in this press release, future clinical development ofSynvista Therapeutics' product candidates, and other risks identified inSynvista Therapeutics' filings with the Securities and Exchange Commission.Further information on risks faced by Synvista are detailed under the caption"Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for theyear ended December 31, 2007. These filings are available on a websitemaintained by the Securities and Exchange Commission at http://www.sec.gov.The information contained in this press
You May Also Like